Funding Support and Author Disclosures Dr Jain has received research funding from the American Heart Association and Janssen Research and Development LLC; and has received consulting fees from Bristol Myers Squibb, ARTIS Ventures, and Broadview Ventures outside of the submitted work. Dr Mortazavi has received research funding from the National Science Foundation (IIS #2014475) and the National Institutes of Health (R21EB028486, R01HL151240, R01EB028106, R01HL142765, and R01DK136414); and is an expert witness working with the law firms of McAndrews, Held, and Malloy and of Kirkland and Ellis, in a patent litigation matter unrelated to topics in this manuscript. Dr You is a chief executive officer of PHI Digital Healthcare; has received grants from Daiichi-Sankyo; and is a coinventor of granted Korea Patents DP-2023-1223 and DP-2023-0920 and pending Patent Applications DP-2024-0909, DP-2024-0908, DP-2022-1658, DP-2022-1478, and DP-2022-1365, unrelated to the current work. Dr Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Novo Nordisk and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Alnylam Pharma, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Biopeutics, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Corteria, CPC Clinical Research, Cytokinetics, Eli Lilly, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research and Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Quidel Corporation, Radcliffe Group Ltd, Roche, and Us2.ai; and serves as cofounder and nonexecutive director of Us2.ai. Dr Elias has received research support to his institution from American Heart Association, Eidos Therapeutics, Pfizer, Janssen Pharmaceuticals, New York Academy of Medicine, Edwards Lifesciences, and Google. Dr Poterucha owns stock in Abbott Laboratories and Baxter International with research support provided to his affiliated institutions from the American Heart Association (Awards #933452 and #23SCISA1077494, https://doi.org/10.58275/AHA.23SCISA1077494.pc.gr.172160), Tianqiao and Chrissy Chen Institute, Eidos Therapeutics, Pfizer, and Edwards Lifesciences. Dr Avram is a coinventor in the patent 63/208,406 (Method and System for Automated Analysis of Coronary Angiograms); has received speaker fees from Abbott, Boston Scientific, Boehringer Ingelheim, and Novartis; has received research support from the Fonds de recherche du Québec (FRQ) through a grant awarded to his research center (grant number FRQ 5232: https://doi.org/10.69777/5232) and a personal career award from the FRQS to Dr Robert Avram (FRQS Award: https://doi.org/10.69777/312758). Dr Tison has received research grants from MyoKardia, a wholly owned subsidiary of Bristol Myers Squibb, and Janssen Pharmaceuticals; and is an advisor to Viz.ai and Prolaio. Dr Schwamm has provided paid consulting for Medtronic on stroke prevention; has unpaid membership on a hospital advisory committee to Abridge, Inc; serves as a content advisor on digital health for stroke; is chair of the American Heart Association AI task force and member of its health tech advisory group; and is a coinventor of an AI-enabled stroke classifier U.S. patent pending application US2024031761. Dr Dunn has received funding from the National Institutes of Health (R01DK133531), National Science Foundation (CAREER #2339669), U.S. Food and Drug Administration, Centers for Disease Control and Prevention, BARDA, and AstraZeneca, and has served as a scientific advisor to Veri, Inc, Biio, Inc, and Google LLC. Dr Spatz has received funding from the National Heart, Lung, and Blood Institute (R01HL151240) and the Patient Centered Outcomes Research Institute (HM-2022C2-28354). Dr Krumholz has received options from Element Science and Identifeye; has received payments from F-Prime for advisory roles; has co-founded and held equity in Hugo Health, Refactor Health, and ENSIGHT-AI; and has been associated with research contracts through Yale University from Janssen, Kenvue, Novartis, and Pfizer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.